ADS032 / Adiso Therap - LARVOL DELTA

Junctional epithelial Plakoglobin facilitates intestinal inflammation by p38MAPK-dependent activation of the inflammasome. (PubMed, Mucosal Immunol) - "These effects were blunted by NLRP1/3 inhibitor ADS032.. These findings identify JUP as a critical modulator of epithelial innate immunity in the gut. The loss of JUP in tissues from CD patients underscores its potential relevance in disease pathology."

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • IL17A • IL18 • IL1B • NLRP1

A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases. (PubMed, Clin Transl Immunology) - "Critically, ADS032 protected mice from lethal influenza A virus challenge, displayed increased survival and reduced pulmonary inflammation. ADS032 is the first described dual inflammasome inhibitor and a potential therapeutic to treat both NLRP1- and NLRP3-associated inflammatory diseases and also constitutes a novel tool that allows examination of the role of NLRP1 in human disease."

Journal • Infectious Disease • Inflammation • Influenza • Pneumonia • Pulmonary Disease • Respiratory Diseases • IL18 • IL1B • NLRP1 • NLRP3 • TNFA